Social-cognitive Functioning: Validation of a New Neuropsychological Test
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 26, 2022
Trial Information
Current as of September 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new test called REALSoCog, designed to better understand social behavior changes in people with certain types of dementia, including Alzheimer's Disease, Lewy Body Dementia, and Frontotemporal Degeneration. The goal is to validate this test to see how well it can detect social-cognitive issues, which are often not recognized during regular doctor visits but are frequently noticed by caregivers. By using a fun, game-like approach, the researchers hope to identify any social behavior problems early, which could lead to more tailored care for patients.
To participate in this study, patients need to be between 18 and 90 years old, have a certain level of mental function, and have a diagnosed neurodegenerative condition. Caregivers who regularly assist the patient are also eligible if they are over 18. Participants can expect to engage in the REALSoCog test, which aims to provide insights into their social behavior and how it relates to their overall well-being. Importantly, the study is not yet recruiting, so interested individuals should stay tuned for updates on when they can join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For patients:
- • Patient aged between 18 and 90 years
- • Mini Mental State Examination (MMSE) score greater than or equal to 20
- • Patient able to express his or her non-opposition to participate in the study in an informed and autonomous manner
- • Patient with a neurodegenerative pathology: FTD, AD or LBD.
- For caregivers:
- • Over 18 years of age
- • Regular contact with the patient (≥ 2 times per month)
- Exclusion Criteria:
- For patients:
- • Neurological or psychiatric comorbidity
- • Notable sensory disorders (e.g., profound or total deafness, age-related macular degeneration, blindness, etc.) that may interfere with experimental completion.
- • Opposition to participation in the study
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Marc VERNY, Pr
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials